TGFB-1 level in breast cancer patients treated with external beam whole breast irradiation versus accelerated partial breast irradiatio
- Conditions
- C50.919Breast cancer.Malignant neoplasm of unspecified site of unspecified female breast
- Registration Number
- IRCT20211212053368N1
- Lead Sponsor
- Ahvaz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 20
Age more than 45 years
Unifocal and unicenric breast cancer less than or equal to 3 cm in size (including various histologies of invasive ductal, Papillary, mucinous, tubular, edullary and lobular carcinoma and low to moderate risk intraductal carcinoma)
No invasion to the lymphovascular space
No lymphatic involvement in invasive histologies
No distant metastasis
Consent to participate in the study
Extensive Intraductal Component (EIC) in breast imaging evaluation
Paget disease of the breast or skin involvement
Synchronous tumor or history of breast cancer
History of malignancy 5 years before enrollment
Pregnancy or lactation
History of collagen vascular disease, or genetic diseases such as ataxia Telangiectasia that leads to increased radiation sensitivity
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum level of Transforming Growth Factor Beta-1 (TGFB-1). Timepoint: Before radiotherapy, immediately after the end of radiotherapy and three months after the end of radiotherapy. Method of measurement: Assessment of serum levels of TGF-beta1 by Enzyme-linked immunosorbent assay technique (ELISA).
- Secondary Outcome Measures
Name Time Method